Aurobindo Pharma

Corporate brand

Indian multinational pharmaceutical company and one of the world's largest generic drug manufacturers, headquartered in Hyderabad.

Last updated October 27, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Aurobindo Pharma Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded in 1986 by a group of entrepreneurs led by P. V. Ramprasad Reddy, the company has grown into one of India's largest pharmaceutical manufacturers and a major global supplier of generic medicines. Aurobindo develops, manufactures and markets a broad portfolio of formulations, active pharmaceutical ingredients (APIs) and intermediates, with a strong presence in anti-infectives, cardiovascular, central nervous system (CNS), anti-diabetics, anti-allergics, gastroenterology and other therapeutic categories. The company operates across the entire pharmaceutical value chain, from API synthesis to finished dosage forms, and is vertically integrated with manufacturing facilities in India and several other countries. Aurobindo is a significant player in the United States generics market, where it ranks among the top generic pharmaceutical companies by prescriptions, and it also has a substantial presence in Europe, particularly through its subsidiary Aurobindo Pharma B.V. and its operations in the Netherlands, Portugal and other European countries. Its products are sold in over 150 countries. Aurobindo is listed on the Bombay Stock Exchange and the National Stock Exchange of India under the ticker AUROPHARMA. The company has pursued growth through both organic expansion and strategic acquisitions, including the acquisition of certain assets from Actavis in Europe and the acquisition of Apotex's operations in several European countries. It has also invested in biosimilars, injectables and specialty pharmaceuticals through its subsidiaries and research and development efforts. In recent years, Aurobindo has focused on expanding its complex generics portfolio, increasing its research and development spending, and strengthening its presence in regulated markets. The company operates a large manufacturing base with multiple US FDA-approved facilities and has faced regulatory scrutiny at some of its plants, which it has worked to address. Aurobindo remains a key player in the global generic pharmaceutical industry and a major contributor to India's pharmaceutical exports.

History

Aurobindo Pharma was founded in 1986 in Hyderabad, India, by a group of entrepreneurs including P. V. Ramprasad Reddy, K. Nithyananda Reddy and Penaka Sarath Chandra Reddy. The company began as a manufacturer of active pharmaceutical ingredients (APIs) and gradually expanded into finished dosage formulations. In its early years, Aurobindo focused on the Indian market and on exporting APIs to regulated and semi-regulated markets. During the 1990s and 2000s, Aurobindo expanded its manufacturing capabilities and obtained approvals from major regulatory authorities, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This allowed the company to enter the lucrative US and European generics markets. Aurobindo grew through a combination of organic expansion and acquisitions. In 2006, it acquired Milpharm Limited in the UK, and in 2007 it acquired Pharmacin International B.V. in the Netherlands. These acquisitions strengthened its European presence. A major turning point came in 2014 when Aurobindo acquired the generics business of Actavis in seven European countries (including France, Italy, Spain, Portugal, the Netherlands, Belgium and Germany) for approximately €30 million. This acquisition significantly expanded its European footprint and product portfolio. In 2015, Aurobindo acquired Apotex's operations in five European countries (Czech Republic, Poland, Romania, Slovakia and the Netherlands), further consolidating its position in Europe. In the United States, Aurobindo became one of the largest generic pharmaceutical companies by prescription volume, benefiting from the wave of patent expirations and the growing demand for affordable medicines. The company invested heavily in research and development, with a focus on complex generics, injectables, biosimilars and specialty products. It also expanded its API business, becoming one of the world's leading API manufacturers. Aurobindo has faced regulatory challenges at some of its manufacturing facilities. In 2017 and subsequent years, the US FDA issued observations and warning letters for certain plants, including its Unit III and Unit VII facilities in Hyderabad and its API plant in Srikakulam. The company has since implemented corrective actions and remediation measures. Despite these challenges, Aurobindo continued to grow, and by the 2020s it was among the top generic pharmaceutical companies globally, with revenues exceeding US$2 billion. In recent years, Aurobindo has focused on expanding its injectables and biosimilars portfolio, increasing its presence in China and other emerging markets, and investing in new manufacturing capacities. The company has also been working on developing complex products such as oncology drugs and respiratory medicines. Aurobindo remains a family-promoted company, with the founding Reddy family holding a significant stake, and it is listed on the Bombay Stock Exchange and the National Stock Exchange of India.

2015
Acquired Apotex operations in five European countries.
2014
Acquired Actavis generics business in seven European countries.
2007
Acquired Pharmacin International B.V. in the Netherlands.
2006
Acquired Milpharm Limited in the UK.
1986
Aurobindo Pharma founded in Hyderabad, India.

Products and positioning

Vertically integrated, cost-competitive global generic pharmaceutical manufacturer with a broad portfolio and strong presence in regulated markets.

Anti-infectives
A broad range of antibiotics and antiviral products.
Cardiovascular drugs
Medicines for hypertension, heart failure and related conditions.
CNS drugs
Products for neurological and psychiatric disorders.
Anti-diabetics
Oral and injectable diabetes treatments.
Injectables
Sterile injectable formulations including antibiotics.
Biosimilars
Biologic products similar to approved reference biologics.

Controversies

2020
Aurobindo Pharma and others sued over alleged metformin contamination concealment
MSP Recovery filed a class action in a U.S. court against Aurobindo Pharma and other drug makers, alleging concealment of information about the cancer-causing agent NDMA in metformin. The article reports that Valisure's tests found NDMA in metformin produced by Aurobindo and Heritage, while also noting that Aurobindo passed the FDA test for NDMA presence.
Source
2020
Astellas files patent-infringement complaint against pharmaceutical companies
Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the '780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.
Source

Sources9 sources

Cite this profile: Cite the canonical profile. /brand-wiki/aurobindo-pharma · Editorial policy · How profiles are compiled